Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.
AuthorsBleehen, N M
Girling, D J
Leonard, R C
McKenzie, C G
Morgan, D A
Smyth, J F
Spittle, M F
Stephens, R J
AffiliationMRC Clinical Oncology and Radiotherapeutics Unit, Addenbrooke's Hospital, Cambridge, UK.
MetadataShow full item record
AbstractResults from a long-term follow-up suggest that in patients with limited small-cell lung cancer (SCLC) and normal performance status intensive alternating chemotherapy and radiotherapy improve long-term survival rates. In a non-randomised study, 22 patients with SCLC of limited extent and good performance status were prescribed six cycles of etoposide, doxorubicin, cisplatin and cyclophosphamide at 4 week intervals with doses of thoracic radiotherapy following the second, third and fourth cycles. Although only six patients received all their prescribed treatment, nine (41%) were alive at 1 year, seven (32%) at 2 years, six (27%) at 3 years, and four are still alive at, respectively, 42, 47, 50, and 61 months, all four being in the subgroup of eight patients with WHO performance status grade 0 at the start of treatment. In a comparison with similar patients receiving conventionally scheduled chemotherapy and radiotherapy in a concurrent trial, no difference in survival was seen in the patients with performance status grade 1 or 2, but a large difference in favour of the alternating schedule in those with grade 0 status was seen. We encourage other investigators to report the results achieved with intensive treatment in patients with WHO grade 0 performance status at the start of treatment.
CitationCan long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party. 1994, 70 (1):142-4 Br. J. Cancer
JournalBritish Journal of Cancer
- [Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
- Authors: Payne DG, Murray N, Warde P
- Issue date: 1994 Feb
- Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung.
- Authors: Murray N, Shah A, Brown E, Kostashuk E, Laukkanen E, Goldie J, Band P, Van den Hoek J, Murphy K, Sparling T
- Issue date: 1986 Sep
- Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study.
- Authors: Gregor A, Drings P, Burghouts J, Postmus PE, Morgan D, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G
- Issue date: 1997 Aug
- Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
- Authors: Ardizzoni A, Fusco V, Pennucci C, Baldini E, Orsatti M, Vitale V, Bonavia M, Baracco F, Mereu C, Rosso R
- Issue date: 1991 Mar-Apr
- A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
- Authors: Bleehen NM, Girling DJ, Machin D, Stephens RJ
- Issue date: 1993 Dec